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Abstract
Background: Urinary tract infections are bacterial infections most commonly encountered in the community. The
resistance rate of uropathogens to commonly prescribed antibiotics has increased worldwide but there are no
published data concerning the resistance of strains isolated from community-acquired UTI in Guadeloupe. To assess
the susceptibility patterns of Enterobacteriaceae strains isolated from outpatients in Guadeloupe we conducted a
prospective study from December 2012 to May 2014 among outpatients consulting at private and public
laboratories for urine analysis. Risk factors for E. coli resistance to amoxicillin, third-generation cephalosporin, and
ciprofloxacin were also determined. To study the trends of E. coli resistance rates over the past 10 years, data on
the susceptibility patterns of E. coli from 2003 to 2014 were also collected from three major laboratories for a
retrospective study.
Results: During the prospective study, we isolated 1293 bacterial strains from the urine of outpatients presenting
for urine analysis. The most commonly isolated bacteria were E. coli (57 %) and Klebsiella pneumoniae (15.5 %).
Thirty seven per cent of the E. coli strains were resistant to amoxicillin. Resistance rates to third generation
cephalosporin were low for E. coli and other Enterobacteriaceae (3.1 and 12.2 % respectively) and mostly due to the
presence of an Extended Spectrum Beta-lactamase. Resistance to cotrimoxazole and ciprofloxacin was moderate
(17.8 and 15.6 % respectively). However, the resistance rate of E. coli to ciprofloxacin has significantly increased
during the last 10 years. Risk factors were consistent with previously reported data, especially for the increasing
ciprofloxacin resistance with age.
Conclusion: General practitioners in Guadeloupe need to be better informed to favor the prescription of
fosfomycin-trometamol to reduce the risk of resistance to fluoroquinolones.
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Background
Urinary tract infections (UTI) are bacterial infections
most commonly encountered in the community, regard-
less of age. UTIs are usually benign and the infection
(cystitis, prostatitis, urethritis) is limited to the lower
urinary tract requires a simple antibiotic treatment.
However, recurrences are common and may evolve into
an upper UTI (pyelonephritis) requiring a heavier anti-
biotic treatment and more extensive management [1].
Enterobacteriaceae, especially Escherichia coli, are the
most prevalent uropathogens in patients with UTI, both
in the community and hospitals [2]. In most cases, the
treatment of uncomplicated UTIs is empirical. The
French Language Infectious Disease Society (SPFIL) rec-
ommends using a single dose of fosfomycin-trometamol
in combination for the first line treatment of UTI and
pivmecillinam for second line therapy. Beta-lactams,
quinolones or cotrimoxazole should be administered
after susceptibility testing since strains resistant to these
antibiotics are frequently isolated. Indeed, multi drug re-
sistant strains are emerging, especially strains harboring
Extended Spectrum Betalactamases (ESBL). ESBL en-
zymes can hydrolyze almost all beta-lactams (except for
carbapenems and cephamycins) and their genes are
often closely linked to other genes that confer resistance
to several other classes of antibiotics. During the past
decade, CTX-M enzymes have gradually replaced the
classical TEM and SHV-type ESBLs in many countries.
The rapid international spread of CTX-M-15 has been
associated with the global dissemination of particular E.
coli clones, such as sequence type 131 [3].
The resistance rate of uropathogens to commonly
prescribed antibiotics has increased worldwide: resist-
ance to quinolones and trimethoprim increased in
Europe between the ECO-SENS I (1999–2000) and
ECO-SENS II (2007–2008) studies and in Africa
(Senegal, Central African Republic) between 2003 and
2006, reducing therapeutic options [4–7].
Guadeloupe, a French overseas territory located in the
Caribbean, is a very high resource country according to
the Human Development Index in 2013. There are no
published data concerning the resistance of strains
isolated from community-onset UTI in Guadeloupe and
data from the Caribbean more generally are rare.
We, therefore, conducted a prospective study, from
December 2012 to May 2014, to assess the suscepti-
bility patterns of Enterobacteriaceae strains isolated
from outpatients and to determine the risk factors
for UTIs due to Enterobacteriaceae resistant to com-
monly used antimicrobial agents. We also studied
the genetic basis for the antibiotic resistance of
ESBL-producing Enterobacteriaceae. Finally, to deter-
mine the recent trends of resistance to antibiotics,
we conducted a retrospective study on the antibiotic
resistance of E. coli isolated from outpatients during
the last 10 years.
Methods
Patients
We collected 1293 bacterial strains isolated from the
urine of outpatients presenting for a urine analysis from
13 of the 23 private Guadeloupian laboratories and the
laboratory of the Hospital of Basse-Terre between
December 2012 and May 2014. All strains responsible
for lower and upper UTI and bacteriuria according to
SPFIL criteria (pyuria ≥104 leucocyte/mL and bacteri-
uria ≥103 for E. coli or S. saprophyticus and ≥104 for
other species) [8] were included in the study. Only
one specimen was collected from each patient. The
leucocyte count, isolation, identification and antibiotic
susceptibility testing of bacteria were conducted by all
laboratories according to their routine diagnostic
procedures. All Enterobacteriaceae strains were sent
to the Pasteur Institute of Guadeloupe for complete
antibiotic susceptibility testing.
The study protocols were approved by the French
Advisory Committee on Information Processing in
Material Research in the Field of Health (CCTIRS
12–220). Written informed consent to participate in
the study was obtained from all patients.
Antibiotic susceptibility testing of Enterobacteriaceae at
the Pasteur Institute of Guadeloupe
We assessed the susceptibility to the following antibi-
otics by the disk diffusion technique on Mueller-Hinton
agar (MH) as recommended by the Antibiogram Com-
mittee of the French Microbiology Society (ACFMS) [9]:
amoxicillin (10 μg), amoxicillin-clavulanic acid (20 μg/
10 μg), ticarcillin (75 μg), cephalothin (30 μg), cefotax-
ime (30 μg), ceftazidime (30 μg), cefoxitin (30 μg), aztre-
onam (30 μg), imipenem (10 μg) gentamicin (15 μg),
amikacin (30 μg), trimethoprim/sulfamethoxazole (1,25/
23,75 μg), nalidixic acid (30 μg), ciprofloxacin (5 μg),
fosfomycin (50 μg), nitrofurantoin (300 μg) and tetracyc-
line (30 UI).. Inhibition growth diameters were measured
using the Adagio automated system (Bio-Rad, France).
Intermediate and resistant strains were grouped together
and classified as resistant strains. Extended spectrum
beta-lactamases were detected for strains with reduced
inhibition growth diameters around cefotaxime, ceftazi-
dime or aztreonam by the combined disk method with
the following combinations: cefotaxime (30 μg) and
ceftazidime (30 μg); cefotaxime (30 μg) and clavulanate
(10 μg); and ceftazidime (30 μg) and clavulanate (10 μg).
The minimum inhibitory concentration (MIC) for
cefotaxime and ceftazidime were determined using the
agar-dilution method as recommended by the ACFMS
for ESBL-carrying strains [9]. The cut-off values used for
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classification were: susceptible strains were defined as
those having a MIC <8 mg/L for cefotaxime, and a MIC
≤4 mg/L for ceftazidime; and resistant strains as those
having a MIC ≥32 mg/L for cefotaxime and a MIC
≥8 mg/L for ceftazidime. E. coli ATCC 25922 was used
as a control stain.
Molecular characterization of ESBL-producing strains
DNA was extracted using the Nucleospin tissue kit
(Macherey Nagel, Hoerdt, France). Previously described
polymerase chain reaction (PCR) methods were used to
screen for plasmid-encoded blaCTX-M, blatem and blaSHV
genes [10–12]. Both blaCTX-M, blaSHV and blaTEM were
then characterized by Direct DNA sequencing of the
PCR products.
The nucleotide and deduced amino acid sequences were
analyzed and compared with sequences available through
the Internet on the National Center for Bio-technology
Information web site (http://www.ncbi.nlm.nih.gov).
Epidemiological data
A standardized specific questionnaire was completed to
collect demographic data. Risk factors for E. coli resist-
ance to amoxicillin, third-generation cephalosporin
(3GC) and ciprofloxacin were assessed from questions
about: age, gender, chronic illness, hospitalization during
the last year, UTI during the previous last 3 months,
urinary catheterization during the previous year, anti-
biotic exposure during the last month, and hospital or
family hospital occupation.
Evolution of antibiotic resistance in E. coli from 2003
To analyze the trends of resistance to antibiotics during
the last 10 years, data were collected on the resistance of
E. coli strains isolated from community-acquired UTIs
in outpatients presenting at the emergency units of the
hospitals of Basse-Terre and Pointe à Pitre and at the
Pasteur Institute of Guadeloupe between 2003 and 2014.
These data were added to that collected during the pro-
spective study for 2013 and 2014.
Data analysis
Statistical analysis was performed using R software (refer-
ence: R Development Core Team. R: A Language and
Environment for Statistical Computing [Internet]. Vienna,
Austria: R Foundation for Statistical Computing; 2010.
Available: http://www.R-project.org/).
We used logistic regression to estimate the relation
between resistance to each antibiotic and the various
covariates (age, gender, clinical symptoms). All covari-
ates with a p value lower than 0.20 were included in the
multivariable model. Multivariable, backward, step-by-
step binomial negative regressions were used to take into
account confounders, bias, and interactions linked to the
dependent variable.
To compare annual resistance rates, we performed
Poisson regression and chi2 tests. Statistical differences
were considered significant for p-values <0.05.
Results
Patients
We collected a total of 1293 strains during the study
period. Most (73.5 %) were isolated from women (sex ra-
tio 0.34). The median age of patients was 57.4 years
(range 0 to 95 years). Sixteen patients carried significant
numbers of two different strains. We obtained epidemio-
logical data for 340 patients; pregnant women accounted
for 10.6 % of women interviewed, and 69 % of patients
had UTI symptoms.
Bacterial strains and antibiotic susceptibility
More than 86 % of the isolates were Enterobacteriaceae:
736 E. coli (57.0 %), 202 Klebsiella pneumoniae (15.5 %),
56 Proteus mirabilis (4.3 %), 54 Enterobacter spp.
(4.2 %), 38 Citrobacter koseri (2.9 %), and 35 other En-
terobacteriaceae (2.7 %). Other Gram-negative bacteria
(Pseudomonas spp. and Acinetobacter spp.) accounted
for 0.6 % of the isolates. Among the isolates, 170 were
Gram-positive bacteria (13.1 %): Streptococcus agalactiae
(4.3 %), Enterococcus faecalis (4.2 %), and Staphylococcus
saprophyticus (2.3 %).
Many of the E. coli isolates were susceptible to numer-
ous drugs, but 42.1 % of the strains were resistant to
amoxicillin and ticarcillin.
A small proportion of strains were not susceptible to
3GC (3.1 % E. coli and 12.2 % other Enterobacteriaceae;
Table 1). Most 3GC-resistant strains had a MIC greater
than 64 mg/L for cefotaxim and ceftazidime (85 and
67.5 %, respectively). This resistance was mostly due to
the presence of an ESBL (n = 39, 85 %): 24 K. pneumo-
niae, 11 E. coli, 3 Enterobacter spp. and one M.
morganii.
Resistance to cotrimoxazole and ciprofloxacin was
17.8 and 15.6 %, respectively.
Resistance rates to fosfomycin and nitrofurantoin were
low among E. coli strains (1.6 and 1.2 % respectively).
These rates were higher for other Enterobacteriaceae:
17.9 % for fosfomycin and 32.6 % for nitrofurantoin.
Only a small proportion of Enterobacteriaceae strains
were resistant to gentamicin (6.4 %) and amikacin
(0.5 %) (Table 1). Only one strain (Morganella morganii)
was resistant to imipenem.
Most 3GC-resistant strains had at least one co-
acquired resistance: 85 % were resistant to ciprofloxacin,
67.5 % to cotrimoxazole and 52.5 % to gentamicin
(Table 2).
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Determinants of antibiotic resistance in 3GC-R
Enterobacteriaceae strains
The 39 ESBL producing strains are described in Table 2.
Among them 38 expressed a CTX-M enzyme including
29 CTX-M15 and 7 CTX-M1. Additional β lactamases
were found in most of strains (87.5 %).
Risk factors for E. coli resistance to amoxicillin,
third-generation cephalosporin and ciprofloxacin
Strains isolated from male patients had a significantly
higher amoxicillin resistance rate than those isolated
from female patients (p = 0.04). The ciprofloxacin re-
sistance rate tended to increase with increasing age
(p < 0.01) (Table 3).
Among 286 patients with an Enterobacteriaceae, 68
(23.7 %) declared to have received antibiotic treatment
during the previous month and 72 (25.2 %) to have had
a UTI during the three previous months. More Entero-
bacteriaceae strains isolated from patients who declared
a UTI during the three previous months were resistant
to amoxicillin (p = 0.02) and ciprofloxacin (p < 0.01)
than those isolated from patients without a UTI dur-
ing the three previous months. Moreover, urinary
catheterization was associated with higher resistance
rates for amoxicillin and cotrimoxazole (p < 0.01)
(Table 3).
Evolution of antibiotic resistance in E. coli from 2003
Resistance rates for amoxicillin, cotrimoxazole and ami-
kacin have been stable during the last 10 years. On the
contrary, we found a significant (p < 0.01) increase in the
Table 1 Susceptibility of outpatients Enterobacteriaceae urinary
isolates to various antimicrobial agents
Number of isolates resistant to antibiotics (%)
E. coli
(n =733)
Other
Enterobacteriaceae
(n =376)
All
Enterobacteriaceae
(n =1109)
Amoxicillin 42.1 88 57.6
Co-amoxiclav 18.6 32.7 23.4
Ticarcillin 38.9 75.8 51.4
Cefalothin 16.7 30 21.2
Cefoxitin 2.7 23.1 4.5
Cefotaxim 3.1 12.2 6.2
Ceftazidim 2.3 12.8 5.7
Aztreonam 1.9 11.7 7
Imipenem − 6.7 2.3
Cotrimoxazole 18.6 16 17.8
Amikacin 0.4 0.5 0.5
Gentamicin 5.4 8.2 6.4
Nalidixic acid 19.7 21.3 20.2
Ciprofloxacin 13.8 19.4 15.6
Fosfomycin 1.6 17.9 7.1
Nitrofurantoin 1.2 32.6 13.7
Tetracyclin 25 32.7 27.6
Table 2 Characteristics of the ESBLEa
Species and
ESBL type
Additionnal β lactamase Acquired co-resistanceb
non ESBL SHV TEM1-like OXA-1 like SXT GM CIP TE
K. pneumoniae (24)
CTX M-15 (21) 16 11 11 14 11 21 11
CTX M-1 (2) 1 1 1 1 2 2 2
SHV-12 (1) - - - 1 - 2 -
E. coli (11)
CTX M-15 (5) - 2 - 3 2 3 3
CTX M-1 (4) - 3 - 4 2 1 3
CTX M-14 (1) - 1 - - 1 1 1
CTX M-27 (1) - 1 1 1 - 1 1
E. cloacae (2)
CTX M-15 (2) - 2 2 2 1 2 1
E. aerogenes
CTX M-1 - - - - - - -
M. morganii
CTX M-15 - - - 1 1 1 1
aNumber of strains is indicated in parentheses when >1
bSXT cotrimoxazole, GM gentamicin, CIP ciprofloxacin, TE tetracyclin
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Table 3 Analysis of independent risk factors for E. coli resistance to amoxicillin, trimethoprim/sulfamethoxazole and ciprofloxacin
Risk factor Number % AMX SXT CIP
Crude OR
[95 %]
P value Ajusted OR
[95 %]
P value OR [95 %] P value Ajusted OR
[95o%]
P value OR [95 %] P value Ajusted OR
[95 %]
P value
Sex - Male 124 19.9 1.5 [1.1–2.3] 0.04 1.4 [0.8–2.2] 0.21 1.6 [0.9–2.7] 0.09
Age category
less than 40 years 168 26.9 Ref Ref Ref
40–59 years 141 23.7 0.9 [0.5–1.4] 0.55 1.1 [0.6–2.0] 0.81 2.7 [1.1–6.9] 0.03
60–69 years 115 21.2 1.1 [0.7–1.8] 0.66 1.9 [1.1–3.4] 0.03 4.5 [1.9–10.9] <0.01
70 year and more 176 28.2 1.2 [0.7–1.8] 0.45 1.9 [1.1–3.3] 0.03 4.8 [2.1–11.3] <0.01
Presence of clinical
signs
147 73.5 0.6 [0.4–1] 0.07 0.5 [0.2–0.9] 0.03 0.9 [0.3–3.1] 0.87 1.2 [0.6–2.6] 0.59
Chronic illness 56 26.7 1.1 [0.7–1.9] 0.64 1.1 [0.3–3.7] 0.91 1.4 [0.7–2.7] 0.41
Prior (3 months) UTI 52 24.8 1.8 [1–3.2] 0.04 2.3 [1.1–4.9] 0.02 3.1 [1–10.1] 0.05 5.4 [2.7–11] <0.01 5.1 [2.5–10.3] <0.01
Prior (12 months)
hospitalization
32 15.2 2.2 [1.2–4.4] 0.02 5.1 [1.6–16.5] <0.01 1.7 [0.8–3.7] 0.2
Prior (6 months)
urinary catheter
14 7 11.6 [2.7–50.6] <0.01 8.8 [1.9–40.8] <0.01 10.1 [2.5–40.4] <0.01 11.1 [2.4–51.6] <0.01 2.1 [0.7–5.7] 0.16
Prior (6 months)
antibiotic exposure
14 21.4 1.4 [0.8–2.4] 0.26 3.8 [1.1–12.9] 0.03 4 [0.9–18.9] 0.07 2.4 [1.2–4.9] 0.02
Only significant adjusted OR are presented
OR odds ratio, UTI urinary tract infection
*Significant difference (P < 0.05)
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reported resistance to nalidixic acid, ciprofloxacin,
cefalotin, and gentamycin (Table 4). The increase in the
3GC resistance rate was not significant as assessed by
the Poisson regression test but was significant as evalu-
ated by the Chi2 test. Until 2008, fewer than 1.0 % of E.
coli strains were resistant to 3GC, but this proportion
increased significantly between 2008 and 2009 (p < 0.01)
and has been stable during the last 5 years (Table 4).
Discussion
As expected, E. coli was the most frequent strain isolated
from urines in Guadeloupe (57.0 % of isolates), but
nevertheless less frequent than in Europe and Canada
(range from 61.0 to 87.5 %) [13–18]. K. pneumoniae was
the second most frequent pathogen (15.5 %), even in
pre-menopausal women, with a rate similar to those re-
ported in Africa and Asia (ranging from 13.8 to 25.5 %)
[6, 19–22]. S. agalactiae was the most frequent Gram-
positive bacteria (4.3 %), whereas generally reported
rates are less than 3 %. The differences in relative preva-
lence may be due to environmental and/or host genetic
factors, or the virulence of the bacterial pathogens. Of
note, the prevalence of diabetes is high (8.2 %) in
Guadeloupe [23] and UTIs due to K. pneumoniae and S.
agalactiae have been reported to be two to three times
more frequent among patients with diabetes than those
without [24].
As previously described, S. saprophyticus was isolated
more frequently from women under 35 years of age than
men or older women [25].
Overall, resistance rates were similar to those observed
in developed countries including mainland France.
Indeed, we found an amoxicillin-resistance rate of
42.1 % for E. coli, similar to the rate of 43.4 % re-
ported for North America [26] and slightly lower than
the rate of 48.3 % reported for Europe [27] . This
contrasts with the reported situation in African and
developing Asian countries where resistance rates may
be as high as 80 % [6, 7, 28, 29].
Moreover, resistance to 3GC was low, and although
this rate increased significantly between 2008 and 2009,
it remains below 4 % for E. coli strains and 7 % for all
Enterobacteriaceae. Guadeloupe should be considered to
be a low prevalence ESBL-producing Enterobacteriaceae
territory as are the European and North American coun-
tries [5, 15, 27, 30]. In our study, blaCTX-M15 was de-
tected in most of the ESBL-producing strains (74.3 %),
highlighting the shift during the 2000s from ESBL
blaTEM/blaSHV to ESBL group 1 blaCTX-M, and in par-
ticular to blaCTX-M15. This is in accordance with other
epidemiological studies of ESBL-producing Enterobacte-
riaceae [31]. Most ESBL-producing strains (97.5 %) were
resistant to other antibiotics in keeping with the ARESC
and ECO-SENS II studies [5, 27]. Surprisingly, most
ESBL-producing strains isolated in our study were K.
pneumoniae, whereas in the community, E. coli strains
with CTX-M enzymes usually predominate [32] because
of the spread of clonal multidrug-resistant E. coli strains
such as clone O25b-ST131 [33]. The prevalence of K.
pneumoniae in our study can be explained not only by
the high proportion of K. pneumoniae strains among
uropathogens, but also by the spread of successful clones
as described in Africa and Asia [34].
We did not isolate any carbapenemase-producing strains,
although these strains have been observed in the
community, even in low prevalence countries such as
England [15] where their presence is often related to travel
in Asia where these strains are endemic [35]. In
Guadeloupe, Enterobacteriaceae carbapenemase-producing
strains have just begun to emerge in hospital settings
with the first description of an NDM-1-producing K.
pneumoniae in 2014 [36], and more recently, of an
OXA-48-producing E. coli [37].
Ciprofloxacin resistance remains moderate (15.6 %)
compared to rates observed in Asia which can be as high
as 75 % [19]. Nevertheless, we found that this rate has
increased significantly during the last 10 years as
described for other countries [6, 15, 26, 38]. Although
Table 4 Trends of resistance rates to various antimicrobial agents of E. coli between 2003 and 2014
Year 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 P value
n E.coli 198 300 338 437 384 399 606 763 854 766 1019 950
Amoxicillin 43 46.6 43 42.3 43.2 44.1 39.7 37.7 45 44.2 41.4 42.9 NS
Cefalotin 8 6.3 7.8 7.3 5.5 6.2 15 14 16.6 17.6 17 20.4 <0.01*
Cefotaxime 0 0.7 0.3 0 0.9 0.2 1.8 2.5 2.7 3 2.6 2.3 <0.01**
Amikacin 0.5 0.0 0.0 0.5 0.6 0.2 0.2 1 0.7 0.3 0.3 0.3 NS
Gentamicin 1 3.3 4.4 2.3 2.6 4.2 3.6 3.9 5.6 5.2 3.4 4.6 <0.01*
Nalidixic acid 5.5 11 UD UD UD 13.4 15 13.1 13.7 17.2 16.2 20.8 <0.01*
Ciprofloxacin 4 5.3 6.8 8.5 9.6 8.5 11.4 8.2 10.9 9.9 9.9 12.3 <0.01*
Cotrimoxazole 18.7 23 21.6 22.4 23.2 23.3 20.9 19 20.5 19.4 18.6 18 NS
UD unavailable data, NS non significant
P values were calculated using the Poisson regression test (*) or the Chi2 test (**). Significant difference P < 0.05
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we were not able to obtain retrospective data on fluoro-
quinolone consumption in Guadeloupe, increasing rates
of ciprofloxacin-resistant strains suggest the inappropri-
ate use of fluroquinolones in outpatients. Among the 48
patients reporting antibiotic consumption during the
month prior to the infection, 15 had consumed a fluoro-
quinolone and among 24 patients that also reported a
previous UTI, 12 received a fluoroquinolones whereas
only one was given fosfomycin. Indeed, ciprofloxacin
resistance in E. coli has been linked with ciprofloxacin
consumption in the same month as the infection and
the month before [39]. The rate of ciprofloxacin resist-
ance tended to increase with age as has been described
for mainland France and Canada [16, 40] Antimicrobial
susceptibility testing of uropathogens is known to
overestimate rates of resistance because antibiograms
are performed mostly if empirical treatment fails, or if
patients have underlying factors [41]. Nevertheless, the
trends remain valid.
Consistent with previous reports [28, 42] we observed
that prior UTI (likely to be associated with prior anti-
biotic treatment) was associated with higher amoxicillin
and ciprofloxacin resistance rates. This suggests the
abusive use of these antibiotics for the treatment of
community acquired infections. Surprisingly, a previous
antibiotic treatment was not associated with such a risk.
Since the use of antibiotics for which the resistance rate
exceeds 10–20 % is associated with an increased risk of
treatment failure and the selection of resistant strains
[43], ciprofloxacin should be administered only if
compatible with the antimicrobial resistance pattern of
the strain.
Conclusions
Although a few patients may have been infected by
hospital-acquired strains, this is the first description of
susceptibility patterns of urinary bacterial strains isolated
from outpatients in Guadeloupe.
The antibiotic resistance rates among urinary bacteria
isolates from outpatients in Guadeloupe are similar to
those of North America and Europe. Nevertheless, this
study highlights the need for general practitioners in
Guadeloupe to be better informed so that they are
encouraged to prescribe fosfomycin-trometamol for the
treatment of UTI to reduce the risk of increasing resist-
ance rates to fluoroquinolones.
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